Treatment of intraurethral condylomata acuminata with surgery and Cidofovir (cas 113852-37-2) instillations in two immunocompromised patients and review of the literature

Add time:08/27/2019    Source:sciencedirect.com

Condylomata acuminata (CA) or anogenital warts are benign proliferative lesions caused by low-risk human papillomaviruses (HPV). Treating CA can be very frustrating for patients and clinicians due to the high recurrence rates. Immunosuppression is associated with larger size of CA that are more frequently resistant to treatment. Surgical approaches tend to be poorly effective in the long-term because of high recurrence rates related to the persistence of HPV-infected cells. In our search to find an agent to treat intraurethral CA with minor or no side effects, we evaluated intraurethral Cidofovir (cas 113852-37-2) in two male patients, who were under immunosuppressing therapy due to organ transplantation and suffered from extensive urethral HPV lesions.Both patients underwent biopsy of the lesions and initial transurethral resection. In our first case, intraurethral cidofovir instillations were started after 2 months due to recurrence after surgical treatment. In our second case, intraurethral cidofovir was administered after surgery because of incomplete resection of extensive lesions. Because of persistent or rapidly recurrent lesions despite intraurethral cidofovir instillations, the first patient needed two additional surgical interventions while the second patient underwent one additional surgical intervention. After surgical intervention, both patients received again adjuvant cidofovir instillations without side effects. Over a period of 56 weeks, both patients received each a total of 28 instillations with cidofovir.Following 3.5 years (patient 1) of the last cidofovir instillation, no recurrences were observed in our first patient. Following 6 months of the last cidofovir instillation (patient 2), two very small recurrent lesions in the most distal part of the urethra were observed in our second patient for which he will receive a cycle of 6 cidofovir instillations in the near future.Intraurethral cidofovir is a safe, easy-to-use, well-tolerated and an effective adjuvant to surgery for extensive intraurethral CA in immunocompromised patients.

We also recommend Trading Suppliers and Manufacturers of Cidofovir (cas 113852-37-2). Pls Click Website Link as below: cas 113852-37-2 suppliers

Prev:Infectious DiseaseEfficacy of Cidofovir (cas 113852-37-2) in Treatment of BK Virus–Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients
Next:Intralesional Cidofovir (cas 113852-37-2) injection for recurrent respiratory papillomatosis in Japan)